Androgen–urate intervention leads¶
Gout weakness and evidence boundary¶
Androgen manipulation and urate handling intersect, but hormone direction alone does not predict serum urate. The usable weakness is narrower: a defined intervention might change an androgen endpoint and an urate-production or urate-transport endpoint at the same exposure. Each axis must be measured independently. The mechanistic background belongs in the androgen–urate axis.
No evidence assembled here establishes a natural substitute for clomiphene, a gout treatment, or a candidate ranking. The retired COMP-015 failed because it treated botanical extracts, purified compounds, related quassinoids, animal results, and in-vitro assays as interchangeable evidence objects.
Source-specific evidence¶
| Evidence object | What was tested | What survives |
|---|---|---|
| Physta Eurycoma longifolia extract | A characterized oral extract was studied for 12 weeks in 105 men. Serum urate appeared in the safety table; week-12 comparisons with placebo were null (p=0.88 at 100 mg/day and p=0.52 at 200 mg/day), and placebo also declined. Clinical Trial — null urate outcome; PMC8254464. |
Human androgen evidence for this exact extract may motivate a dual-axis study. The trial does not show urate lowering and does not transfer to purified eurycomanone or eurycomanol. |
| 70% ethanol E. longifolia stem extract | The extract was tested at 100, 200, and 400 mg/kg in hyperuricemic animals. In the same report, quassinoids 4–7 inhibited hURAT1 at 50 µM; eurycomanone was compound 3 and showed comparatively low activity. Animal Model + In Vitro; PMID 31920654. | The extract and compounds 4–7 are separate urate leads. Neither supplies a Physta result or a purified-eurycomanone efficacy claim. |
| Purified eurycomanol | Oral eurycomanol at 5–20 mg/kg lowered serum urate, increased 24-hour urate clearance, decreased hepatic PRPS expression, and changed renal and intestinal transporter measurements in hyperuricemic mice. Animal Model; PMID 34785103. | A purified-compound urate lead survives. Concurrent expression, clearance, and transporter changes do not establish direct PRPS binding, causal PRPS-flux control, or human efficacy. |
| Purified cordycepin | Oral cordycepin at 15, 30, and 60 mg/kg lowered serum urate and changed renal URAT1 expression in hyperuricemic mice. Animal Model; PMID 29422889. | Cordycepin remains an exact-material urate lead. Whole Cordyceps, cordycepin, and cordycepin-plus-pentostatin preparations are not evidence-equivalent. |
| Enclomiphene and racemic clomiphene | Clinical studies measured endocrine and reproductive outcomes. The cited studies did not establish a matched-exposure urate comparison. Clinical Trial for endocrine outcomes; Mechanistic Extrapolation for urate. | Their different hormone profiles make a controlled urate comparison testable; they do not establish a urate direction or a preferred intervention. |
Evidence objects that do not yet bridge both axes¶
Boron, magnesium, zinc, DIM/I3C, Fadogia agrestis, cistanche, epimedium, Kampo formulas, and other androgen-associated materials have heterogeneous evidence and safety profiles. An androgen signal, deficiency-correction effect, traditional use, or animal endocrine result is not an urate result. They enter this program only after exact identity, exposure, an androgen endpoint, and an independently supported urate mechanism can be specified.
Sourcing, delivery, and exposure¶
The scientific unit is the tested material, not the species name or product category.
- Characterize identity. A named extract requires a composition fingerprint and lot record. A purified compound requires orthogonal identity and purity checks. Extract ratios and botanical names do not establish equivalent quassinoid or cordycepin exposure.
- Preserve preparation boundaries. Physta, a 70% ethanol stem extract, purified eurycomanone, and purified eurycomanol are four different evidence objects. Whole Cordyceps can change cordycepin stability through associated metabolites, but that does not make whole material equivalent to purified cordycepin.
- Measure delivered exposure. Oral animal administration establishes a route used in those models, not human target-compartment exposure. Free concentration, metabolism, and time above the assay-relevant range must be measured for the exact preparation.
- Separate compartments and mechanisms. Serum urate, urinary clearance, transporter expression, transporter flux, PRPS expression, and isotope-resolved purine flux are different readouts. Movement in one does not prove the others.
- Carry safety with the material. Botanical source, extraction process, impurities, endocrine activity, and off-target effects must be assessed for the same lot used in the efficacy assay.
Research conjecture¶
Research conjecture — an exact material can separate androgen benefit from urate liability
Grounded premises: Characterized E. longifolia preparations have human androgen evidence (Clinical Trial). Purified cordycepin, a source-specific E. longifolia extract, selected quassinoids, and purified eurycomanol supply separate urate leads (Animal Model and In Vitro; PMID 29422889, PMID 31920654, and PMID 34785103). Physta's human urate comparison was null (Clinical Trial — null urate outcome; PMC8254464).
Novel leap: One compositionally verified material might improve an androgen endpoint without worsening urate, or might improve both, at the same measured exposure. No direct evidence tests this dual-axis connection.
Why it matters: A positive result would expose an androgen–urate control point without assuming that all androgen manipulation carries the same urate effect.
Discriminating observation: Run the matched design in validation §2.8. Require identity, exposure, androgen endpoints, urate mass balance, direct transporter or PRPP-flux readouts, and safety for each material. A null rejects only the tested material–exposure configuration.
Experimental program¶
- Qualify one evidence object. Fix the material, lot, identity method, purity or composition fingerprint, vehicle, and exposure measurement.
- Test the axes separately. Measure androgen outcomes and urate mass balance without using either as a proxy for the other.
- Localize the urate effect. If urate changes, distinguish production from excretion with direct flux and transporter-function measurements. PRPS expression alone is insufficient.
- Test causality. Use matched positive and negative controls, perturbation/rescue where feasible, and predeclared decision rules.
- Advance only the exact configuration. A positive result does not transfer to a related compound, extract, formulation, or species.
The clomiphene-specific exposure question remains in H10. The earlier intestinal estrogen-receptor mechanism in H07 is retracted.